- Email: [email protected]
Emefcy and RWL Water merge and form Fluence
news
Evoqua plans to go public
E
voqua Water Technologies LLC has confidentially submitted a draft registration statement on Form S-1 with the US Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) of its common stock. The number of shares to be offered and the price range for the proposed offering have yet to be determined. Formerly Siemens Water Technologies, Evoqua Water Technologies specializes in water and wastewater treatment products, systems and services for industrial and municipal customers. Private equity firm AEA Investors LP acquired Siemens Water Technologies in January 2014 and renamed the business Evoqua Water Technologies. Since then, Evoqua Water Technologies has made a number of acquisitions including ADI Systems, Delta Ultraviolet Corp, Environmental Treatment Systems Inc, Magneto Special Anodes BV, Neptune Benson Inc, Noble Water Technologies, Olson Irrigation Systems and VAF Filtration Systems.
For further information, visit www.evoqua.com
Emefcy and RWL Water merge and form Fluence
E
mefcy Group Ltd and RWL Water LLC have completed their merger and formed Fluence Corp Ltd (see Filtration Industry Analyst, May 2017). Fluence has been established with the vision of becoming the leading global provider of fast-to-deploy decentralized and packaged water and wastewater treatment solutions. Headquartered in New York, Fluence has operating and regional entities located around the world, including the US, China, Australia, Mexico, Argentina, Brazil, Italy, France, Israel and Dubai. The company employs more than 300 water professionals. Henry Charrabé, president and CEO of RWL Water, and Philippe Laval, chief operating officer of RWL Water, have been appointed CEO and COO of Fluence, respectively. Eytan Levy, co-founder and CEO 16
Filtration Industry Analyst
of Emefcy, has been named Fluence’s president – Products & Innovation of Fluence, while Emefcy co-founder Ronen Schechter will serve as chief technology officer of Fluence. “The combination of complementary decentralized and packaged water and wastewater treatment options is paving the way for Fluence to emerge as the leading global provider of innovative water and wastewater solutions serving municipal, industrial and commercial markets,” said Charrabé. “The merger will substantially accelerate Emefcy’s deployment in China and other key markets while making significant operational and distribution gains,” said Richard Irving, executive chairman of Fluence. For further information, visit www.fluencecorp.com
De.mem establishes Singapore membrane production facility
D
e.mem Ltd has opened a facility in Singapore to produce hollow fibre membranes and membrane modules for industrial and municipal wastewater projects. At the new facility, Singapore-based wastewater treatment company De.mem will produce its proprietary filtration technology – the low-pressure hollow fibre nanofiltration (NF) membrane which was developed at Nanyang Technological University, Singapore (NTU). The technology, which NTU exclusively licenced to De.mem in June 2016, is said to allow for lower operating cost and reduced investment relative to other water treatment technologies. The new De.mem facility located in Woodlands has the capacity to produce membranes as well as industry standard 4-inch and 8-inch membrane modules at volumes which are sufficient for small-scale commercial projects. It will also be possible to manufacture other types of hollow fibre membranes at the new site. De.mem is currently preparing for pilot testing at select customer sites ahead of planned commercial market launch of the technology later this year. “We are excited about starting our own membrane production so soon after the successful IPO of ourcompany,” said De.mem CEO Andreas Kroell.
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Executive Publisher: Laney Priestley Subscription Information An annual subscription to Filtration Industry Analyst includes 12 issues and online access for up to 5 users. Subscriptions run for 12 months, from the date payment is received.
More information: www.elsevier.com/journals/institutional/filtrationindustry-analyst/1365-6937 Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Digitally Produced by Mayfield Press (Oxford) LImited 12976
For further information, visit www.demembranes.com milestone,” said De.mem CEO Andreas Kroell.
July 2017
Evoqua plans to go public
E
voqua Water Technologies LLC has confidentially submitted a draft registration statement on Form S-1 with the US Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) of its common stock. The number of shares to be offered and the price range for the proposed offering have yet to be determined. Formerly Siemens Water Technologies, Evoqua Water Technologies specializes in water and wastewater treatment products, systems and services for industrial and municipal customers. Private equity firm AEA Investors LP acquired Siemens Water Technologies in January 2014 and renamed the business Evoqua Water Technologies. Since then, Evoqua Water Technologies has made a number of acquisitions including ADI Systems, Delta Ultraviolet Corp, Environmental Treatment Systems Inc, Magneto Special Anodes BV, Neptune Benson Inc, Noble Water Technologies, Olson Irrigation Systems and VAF Filtration Systems.
For further information, visit www.evoqua.com
Emefcy and RWL Water merge and form Fluence
E
mefcy Group Ltd and RWL Water LLC have completed their merger and formed Fluence Corp Ltd (see Filtration Industry Analyst, May 2017). Fluence has been established with the vision of becoming the leading global provider of fast-to-deploy decentralized and packaged water and wastewater treatment solutions. Headquartered in New York, Fluence has operating and regional entities located around the world, including the US, China, Australia, Mexico, Argentina, Brazil, Italy, France, Israel and Dubai. The company employs more than 300 water professionals. Henry Charrabé, president and CEO of RWL Water, and Philippe Laval, chief operating officer of RWL Water, have been appointed CEO and COO of Fluence, respectively. Eytan Levy, co-founder and CEO 16
Filtration Industry Analyst
of Emefcy, has been named Fluence’s president – Products & Innovation of Fluence, while Emefcy co-founder Ronen Schechter will serve as chief technology officer of Fluence. “The combination of complementary decentralized and packaged water and wastewater treatment options is paving the way for Fluence to emerge as the leading global provider of innovative water and wastewater solutions serving municipal, industrial and commercial markets,” said Charrabé. “The merger will substantially accelerate Emefcy’s deployment in China and other key markets while making significant operational and distribution gains,” said Richard Irving, executive chairman of Fluence. For further information, visit www.fluencecorp.com
De.mem establishes Singapore membrane production facility
D
e.mem Ltd has opened a facility in Singapore to produce hollow fibre membranes and membrane modules for industrial and municipal wastewater projects. At the new facility, Singapore-based wastewater treatment company De.mem will produce its proprietary filtration technology – the low-pressure hollow fibre nanofiltration (NF) membrane which was developed at Nanyang Technological University, Singapore (NTU). The technology, which NTU exclusively licenced to De.mem in June 2016, is said to allow for lower operating cost and reduced investment relative to other water treatment technologies. The new De.mem facility located in Woodlands has the capacity to produce membranes as well as industry standard 4-inch and 8-inch membrane modules at volumes which are sufficient for small-scale commercial projects. It will also be possible to manufacture other types of hollow fibre membranes at the new site. De.mem is currently preparing for pilot testing at select customer sites ahead of planned commercial market launch of the technology later this year. “We are excited about starting our own membrane production so soon after the successful IPO of ourcompany,” said De.mem CEO Andreas Kroell.
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Executive Publisher: Laney Priestley Subscription Information An annual subscription to Filtration Industry Analyst includes 12 issues and online access for up to 5 users. Subscriptions run for 12 months, from the date payment is received.
More information: www.elsevier.com/journals/institutional/filtrationindustry-analyst/1365-6937 Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Digitally Produced by Mayfield Press (Oxford) LImited 12976
For further information, visit www.demembranes.com milestone,” said De.mem CEO Andreas Kroell.
July 2017